scholarly journals Abnormal liver function tests in the patient transplanted 3 years ago for alcoholic liver disease

2006 ◽  
Vol 12 (S2) ◽  
pp. S76-S82
Author(s):  
Nathan M. Bass ◽  
Bernard C. Portmann ◽  
Michael R. Lucey
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Alcoholic Liver Disease ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests

scholarly journals Pregnancy-associated liver disease: a curriculum-based review

2018 ◽  
Vol 9 (3) ◽  
pp. 170-174 ◽  
Author(s):  
Claire Kelly ◽  
Marinos Pericleous
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Liver Diseases ◽  
Pregnant Patient ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Common Reason ◽  
Blood Tests ◽  
Function Tests ◽  
Unique Potential

Pregnancy is associated with changes in normal physiology, including changes to the normal parameters for blood tests. Abnormal liver function tests are a common reason for referral to gastroenterology. However, in the pregnant patient, there are unique potential causes. It is of prime importance to be aware of pregnancy-specific liver diseases as they can be serious and progress rapidly affecting outcomes for both the mother and fetus. Here, we provide an overview of the manifestations of pregnancy-related liver diseases and discuss their potential consequences.

scholarly journals Safety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan Failure

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Anita Verma ◽  
Georg Auzinger ◽  
Michal Kantecki ◽  
James Campling ◽  
Dean Spurden ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Liver Transplant ◽  
Fungal Infection ◽  
Multiorgan Failure ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Safety And Efficacy ◽  
Function Tests ◽  
Clinical Records

Abstract Background The objective of this study was to review our clinical experience on the safety and efficacy of anidulafungin, an echinocandin antifungal, in the treatment of invasive fungal infections (IFIs) in patients with moderate to severe abnormal liver function tests or multiorgan failure and IFI, in a large United Kingdom Liver Centre. Methods The clinical records of the first 50 consecutive patients treated for IFI with anidulafungin between January 7, 2009 and March 2, 2011 were analyzed. Data were collected on demographics, underlying disease, disease characteristics, hematological and biochemical parameters, IFI, concomitant bacterial and viral infections, response to anidulafungin, and anidulafungin-related adverse events. Results The patients’ median age was 54.3 years (range, 19.6–75.9); 60% were male. Twenty-two (44%) patients were liver transplant recipients. Others had hepatopancreaticobiliary disease (n = 15, 30%) or chronic liver disease (n = 11, 22%). Invasive fungal infection (predominantly Candida spp) was proven in 36 (72%) patients, probable in 14 (28%). Of 46 evaluable patients, 35 (76%) had a favorable anidulafungin treatment outcome. Forty-nine (98%) had abnormal liver function tests (LFTs) pretreatment; 31 (62%) had ≥1 LFT raised to ≥2× baseline during anidulafungin treatment. Conclusions In this highly specialized group of patients, anidulafungin treatment was efficacious and well tolerated by those with decompensated liver disease, multiorgan failure, and high-risk liver transplant with proven or probable IFI.

Alpha 1 Anti Trypsin Levels in Asymptomatic Patients with Abnormal Liver Function Tests

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
BJ Egan ◽  
S Sarwar ◽  
M Anwar ◽  
C O'Morain ◽  
B Ryan
Keyword(s):  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests ◽  
Asymptomatic Patients

scholarly journals Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure

2021 ◽  
Vol 10 (8) ◽  
pp. 1730
Author(s):  
Hiroshi Miyama ◽  
Yasuyuki Shiraishi ◽  
Shun Kohsaka ◽  
Ayumi Goda ◽  
Yosuke Nishihata ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Adverse Outcomes ◽  
Long Term Outcomes ◽  
Function Tests ◽  
Parameter Values

Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.

scholarly journals Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock

2017 ◽  
Vol 120 (7) ◽  
pp. 1090-1097 ◽  
Author(s):  
Toni Jäntti ◽  
Tuukka Tarvasmäki ◽  
Veli-Pekka Harjola ◽  
John Parissis ◽  
Kari Pulkki ◽  
...  
Keyword(s):  
Liver Function ◽  
Cardiogenic Shock ◽  
Prognostic Significance ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests
Sign in / Sign up

Export Citation Format

Share Document